pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
Phase I study of MGY825 in patients with lung cancer
Phase 1 · other · Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients
Phase I study of MGY825 in patients with lung cancer for Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients is a Phase 1 program (other) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CMGY825A12101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1
- Modality
- other
- Indication
- Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients
- Status
- active
- Trials
- 1